Publications found:
210
Sort by:
Merck - Celltrion filed first mAB Biosimilar in Europe: Remicade Challenged
US$ 90.00
Celltrion filed infliximab biosimilar (CT-P13) in Europe and was accepted for review by EMA. It is the first biosimilar mAb to be filed for approval in Europe. The patent ... Celltrion conducted PhI and PhIII clinical trials with the duration of 12 months in more than 850 patients. It has already filed Infliximab ...
April 2012
1 pages
Global Biosimilars Market Forecast to 2015
US$ 1,500.00
The biosimilars industry has been growing stupendously across the globe for past few years. Increasing healthcare costs and rising aging population are driving the industry, which stands at a vivid po...
March 2012
140 pages
Global Biosimilars Market Analysis
US$ 1,400.00
Single User PDF Format: US$ 1,400.00
Multi-User License: US$ 1,800.00
Hard Copy: US$ 1,500.00
CD-ROM: US$ 1,500.00 The global biosimilars industry has been growing stupendously since t...
July 2011
65 pages
Biosimilars Update
US$ 695.00
From Canada and the US to Japan, the EU and Australia, regulators around the world are establishing guidelines that will pave the way for competition between biosimilars and costly biologics. For many...
April 2011
140 pages
Biosimilars Regulatory Update: an Evolving Landscape
US$ 395.00
They’re costly to develop, fraught with potential patient safety concerns and subject to regulations that have yet to be written. Yet for the pharmaceutical industry, biosimilar monoclonal antibodies...
February 2011
59 pages
Biosimilars: Surveying the Market Landscape
US$ 395.00
Worldwide, the story is the same. Governments want cheaper drugs for their populations, while the number and kinds of diseases affecting them continue to evolve and grow. Since 1976, when Genentech be...
October 2010
75 pages
Biosimilars: Market Research Report
US$ 3,950.00
This report analyzes the worldwide markets for Biosimilars in US$ Million. The report provides separate comprehensive analytics for US, Europe, and Japan. ... , Shantha Biotechnics Ltd., Teva Pharmaceutical Industries Ltd., and Wockhardt Ltd. Market data and analytics are derived from primary and secondary ...
April 2010
390 pages
Biosimilars (2009 - 2014)
US$ 3,390.00
... numerous opportunities in the global biosimilars market. The global biosimilars market is expected to be worth US$19.4 billion by 2014, growing at a CAGR of 89.1% from 2009 to 2014. The biosimilars market is segmented into ... of the global biosimilars market. The American market is expected to dominate in 2014 after the U.S. market opens up in 2010. Currently, the global biosimilars market is highly ...
September 2009
189 pages
